Auricular Point Acupressure: Examining the Scientific Underpinnings of Pain Relief

Chemotherapy-induced peripheral neuropathy (CIPN)-numbness, burning and stunning pain distributed in hands and feet-is a major challenge among cancer patients. Even after completion of chemotherapy, CIPN persists among ~30-40% of cancer patients, which can negatively impact quality of life. The only drug (duloxetine) better than placebo in a randomized control trial improved pain intensity by 0.72 points on a scale of 0-10, which cannot manage CIPN effectively. A better pain management strategy clearly needs to be developed.

The investigators propose to test auricular point acupressure (APA), a non-invasive, easily administered, patient-controlled, and non-pharmacological strategy, to provide rapid, safe, and effective pain relief so that cancer patients can self-manage their CIPN. APA involves an acupuncture-like stimulation of the ear without needles. With APA, small seeds are taped to specific ear points. The patient is taught to apply pressure to the seeds, with the thumb and index finger, three times a day (morning, noon, and evening) for three minutes each session to achieve pain relief. The investigators have developed a detailed APA protocol to teach health-care providers without experience in acupuncture and traditional Chinese Medicine that investigators can learn about APA in brief educational seminars as a treatment including the systematic identification of ear points (called auricular diagnosis). The investigators teach methods that enable patients to continue using APA to self-manage their pain. However APA is not available in current U.S. health care setting yet.

Quantitative sensory testing (QST) and fMRI in acupuncture have provided new objective methods for measuring pain. QST provides an evaluation of peripheral and central mechanisms of pain by quantifying stimulus-evoked negative and positive sensory phenomena to evaluate a participant's perception of threshold values regarding pain generated through touch (A beta fibers), warmth (C fibers), cold (A delta fibers), and heat (C fibers). Studies have demonstrated changes in heat, pressure, and mechanical pain thresholds immediately following acupuncture; however no study in APA yet. Brain imaging studies in acupuncture indicate that acupuncture can restore normal functional connectivity related to pain reduction. In conjunction with the investigators pilot data demonstrating that APA impacts neural-immune signaling in patients with chronic low back pain, the investigators hypothesize that APA may likewise induce pain relief through the stimulation of A beta fibers and/or C fibers to increase the pain threshold, endogenous opioid binding (releasing inflammatory cytokines), and alter brain networks of central processing in the hypothalamic-pituitary-adrenocortical axis to achieve analgesia.

The investigators plan to study the mechanisms underpinning pain sensitivity and pain processing due to APA on CIPN. Along with the clinical and subjective CIPN outcomes, objective outcomes will include physiological change in pain sensory thresholds (measured by quantitative sensory testing), brain change associated with pain processing (measured by fMRI), and neuro-transmitters (measured by inflammatory cytokines).

Study Overview

• Status: Terminated
• Conditions: Chemotherapy-induced Peripheral Neuropathy (CIPN)
• Intervention / Treatment: Behavioral: Auricular Point Acupressure; Behavioral: Control Auricular Point Acupressure-

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • Johns Hopkins Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Cancer patients who are 18 years of age or olde
• Able to read and write English
• Have CIPN due to received neurotoxic chemotherapy for cancer
• Had average intensity of pain due to CIPN ≥ 4 on a 11-point numerical pain scale in the previous week
• Pain > 3 months duration attributed to CIPN.

Exclusion Criteria:

• Use of an investigational agent for pain control concurrently or within the past 30 days;
• Use of an implantable drug delivery systems, e.g. Medtronic Synchromed
• Prior celiac plexus block, or other neurolytic pain control treatment
• Other identified causes of painful paresthesia existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology
• Allergy to latex (the tapes for the APA include latex).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Factorial Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Auricular Point Acupressure; Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.	Behavioral: Auricular Point Acupressure; Light touch using vaccaria seeds on specific points of the ear
Sham Comparator: Control Auricular Point Acupressure; Auricular points not related to CINP will be used for the intervention.	Behavioral: Control Auricular Point Acupressure-; Light touch using vaccaria seeds on different points of the ear (compared to the APA group).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Pain intensity as assessed by the Brief Pain Inventory-short form (BPI-sf) questionnaire	The Brief Pain Inventory-short form (BPI-sf) questionnaire includes assessment of pain location and multiple aspects of severity of pain, numbness, tingling, and stiffness, including worst, least, average pain, and present, as well as the interference with daily activities. The Brief Pain Inventory-short form (BPI-sf) has a total score ranging from 0 to 10 with higher scores indicating more pain.	Baseline, weekly upto 4 Weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Quantitative Sensory Testing (QST) score	Quantitative Sensory Testing will be measured by cold pressor testing, conditional pain modulation, mechanical pain threshold. The percentage of change score (from each end point to baseline) will be used (0-100) with higher scores indicating less pain	Baseline, weekly upto 4 weeks
Change in pain response assessed by functional MRI Scan	The baseline rs-fMRI will be performed, followed by 10 min of APA. Immediately after the treatment, a repeat fMRI will then be performed. All MRIs will be acquired on a 3.0 Tesla Siemens Trio Tim system (Siemens Medical Solutions, Erlangen, Germany) using a 12-channel head matrix coil T2*-weighted bold functional images covering entire cerebrum and cerebellum. fMRI will take ~45 minutes. The imaging data will be processed using Statistical Parametric Mapping version 8.	baseline, post-4weekly APA treatment, and one month followup
Change in functional status as assessed by the e Patient-Reported Outcomes Measurement Information System (PROMIS) 29 scale	PROMIS 29 will be used to assess Anxiety, Depression, Fatigue, and Sleep Disturbance.The PROMIS-29 scale, which includes: Pain Interference - 4 items; Pain Intensity- 1 item; Physical Function - 4 items; Fatigue - 4 items;Depression - 4 items; Anxiety - 4 items; Sleep Disturbance - 4 items; Satisfaction with Social Participation- 4 items	weekly up to one month post-intervention
Change in Inflammatory Cytokines	It will be measured by blood serum	baselines, weekly upto 4 weeks

Collaborators and Investigators

• Sponsor: Johns Hopkins University
• Investigators: Principal Investigator: Chao Hsing Yeh, Johns Hopkins University

Study record dates

Study Major Dates

• Study Start (Actual): February 15, 2018
• Primary Completion (Actual): January 30, 2019
• Study Completion (Actual): January 30, 2019

Study Registration Dates

• First Submitted: March 5, 2018
• First Submitted That Met QC Criteria: August 14, 2018
• First Posted (Actual): August 16, 2018

Study Record Updates

• Last Update Posted (Actual): March 29, 2021
• Last Update Submitted That Met QC Criteria: March 26, 2021
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neuromuscular Diseases; Peripheral Nervous System Diseases
• Other Study ID Numbers: IRB00119665

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: Have not decided since this is a pilot study.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No